Novonesis completes MicroBioGen deal as Novonesis stock gains 1.15 percent

Published on 10/05/2026 at 11:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 9.60 percent to EUR 1.12 billion. Novonesis stock costs EUR 56.36 on October 5, 2026 versus EUR 55.72.

Architekturrender eines Forschungscampus mit Glasfassade und Gruenflaechen — Architektur-Rendering eines modernen Biotech-Forschungsgebaeudes von Novonesis (Novozymes), ISIN DK0060336014, mit Glasfassade und nachhaltigem Campus-Design, Illustration mit AI erstellt.

Novonesis (ISIN DK0060336014) stock was trading at EUR 56.36 at Lang & Schwarz on October 5, 2026 at 11:37 a.m. CEST, up 1.15 percent versus the prior close of EUR 55.72. As Markets Insider reported on October 1, 2026, Novonesis completed its acquisition of MicroBioGen after receiving all regulatory approvals.

Yeast technology moves in house

The transaction brings the Australian biotechnology company fully into Novonesis after an existing investment and collaboration. According to Markets Insider, the deal strengthens Novonesis' yeast and research capabilities and supports its 2030 strategy.

The latest operational signal is the expansion of the West Allis, Wisconsin facility. Enid News reported on September 28, 2026, that the project expands North American production capacity for dairy cultures and positions the site among the world's largest lactobacillus facilities.

Revenue growth meets a valuation test

In the second quarter of 2026, revenue increased 9.60 percent year over year to EUR 1.12 billion, while net income rose 26.00 percent to EUR 171.70 million. Simply Wall St reported that earnings per share reached EUR 0.37, up from EUR 0.29 in the second quarter of 2025, while profit margin increased to 15.00 percent from 13.00 percent.

That combination gives the acquisition a measurable operating backdrop: Novonesis is adding technology while quarterly revenue and profit are expanding. The counter-factor is execution. Simply Wall St identified integration of MicroBioGen's research pipeline and commercial relationships as a risk in its October 2, 2026 update.

Stock stays below its yearly high

Novonesis has a DKK 117.1 billion market capitalization as of October 5, 2026. Its primary-market quote was DKK 421.20 on Nasdaq Copenhagen at 9:39 a.m. UTC on October 5, 2026, while the 52-week range was DKK 336.80 to DKK 465.00.

The Lang & Schwarz move puts the euro quote 1.15 percent above its prior close, while the Danish-market range places the primary-market price DKK 43.80 below the yearly high. The next investor test is whether the MicroBioGen integration and expanded dairy capacity can extend the growth already visible in the second-quarter figures.

Novonesis stock gains with growth in view

Novonesis stock was trading at EUR 56.36 at Lang & Schwarz on October 5, 2026 at 11:37 a.m. CEST, plus 1.15 percent versus the prior close of EUR 55.72. The further course of trading is shown by the continuously updated real-time quote of Novonesis stock.